VistaGen Therapeutics EBIT

: $-37.28 Mil (TTM As of Dec. 2021)

View and export this data going back to 2011. Start your Free Trial

VistaGen Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2021 was $-10.54 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2021 was $-37.28 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. VistaGen Therapeutics's annualized ROC % for the quarter that ended in Dec. 2021 was -539.20%. VistaGen Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -1,251.19%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. VistaGen Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -25.07%.

VistaGen Therapeutics EBIT Historical Data

The historical data trend for VistaGen Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VistaGen Therapeutics Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

EBIT

-9.82

-13.91

-24.58

-20.76

-17.92

VistaGen Therapeutics Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
EBIT																-5.30	-6.21	-7.74	-12.79	-10.54

VistaGen Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.28 Mil.

VistaGen Therapeutics (NAS:VTGN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

VistaGen Therapeutics's annualized ROC % for the quarter that ended in Dec. 2021 is calculated as:

	ROC % (Q: Dec. 2021 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2021 )	+	Invested Capital (Q: Dec. 2021 ))	/ count )
=	-42.16 * ( 1 - 0% )	/	( (7.877	+	7.761)	/ 2 )
=	-42.16	/	7.819
=	-539.20 %

where

	Invested Capital		(Q: Sep. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	100.5	-	4.098	-	( 93.627	-	max(0, 7.912	-	96.437	+	93.627	))
=	7.877

	Invested Capital		(Q: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	90.536	-	2.426	-	( 83.7	-	max(0, 6.421	-	86.77	+	83.7	))
=	7.761

Note: The Operating Income data used here is four times the quarterly (Dec. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

VistaGen Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2021 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2021		Q: Dec. 2021
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-42.14	/	( ( (3.526 + max(-4.7, 0))	+	(3.21 + max(-2.927, 0)) )	/	2 )
=	-42.14	/	( ( 3.526	+	3.21 )	/	2 )
=	-42.14	/	3.368
=	-1,251.19 %

where Working Capital is:

	Working Capital		(Q: Sep. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.81)	-	(4.098	+	1.42	+	1.992)
=	-4.7

	Working Capital		(Q: Dec. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.07)	-	(2.426	+	1.42	+	2.151)
=	-2.927

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2021) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

VistaGen Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2021 )
	=	-37.28	/	148.687
	=	-25.07 %

VistaGen Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

VistaGen Therapeutics Business Description

Industry

Healthcare » Biotechnology NAICS : 325412 SIC : 2834

Comparable Companies

NAS:CLVS NYSE:ZYME XKRX:078160 XKRX:321550 NAS:RLYB NAS:VSTM OSL:ULTI NAS:XERS NAS:KRON NAS:STRO

Traded in Other Exchanges

N/A

Address

343 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.vistagen.com

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.

Executives

Saxe Jon S	director	FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076
Dotson Jerrold Duane	officer: VP, CFO AND SECRETARY	5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Singh Shawn	director, officer: CHIEF EXECUTIVE OFFICER	C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Snodgrass H. Ralph	director, officer: PRES./CHIEF SCIENTIFIC OFFICER	384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan	officer: CHIEF MEDICAL OFFICER	343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Mcpartland Mark A.	officer: VP CORPORATE DEVELOPMENT	C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B	director	343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Underdown Brian J.	director	C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Cunningham Ann Michelle	director	255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Rice A. Franklin	officer: VP CORPORATE DEVELOPMENT	384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Bonfiglio Gregory A.	director	384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc	10 percent owner	152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Cato Holding Co	10 percent owner	4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Cato Allen Easley	10 percent owner	4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Jones Stephanie	director, 10 percent owner, officer: PRESIDENT	13834 W. HOYT ROAD RATHDRUM ID 83858

VistaGen Therapeutics Headlines

From GuruFocus

VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors

By Marketwired 07-22-2021

VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder

By Marketwired 10-14-2021

VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B's Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain

By Marketwired 10-05-2021

Longwood Capital Partners LLC Buys VistaGen Therapeutics Inc, Seelos Therapeutics Inc, ESSA Pharma Inc, Sells Larimar Therapeutics Inc, Immunovant Inc, Sage Therapeutics Inc

By insider 05-17-2021

VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2

By Marketwired 09-13-2021

VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021

By Marketwired 06-25-2021

Other Sources

$VTGN - VistaGen Therapeutics (VTGN) Investor Presentation - Slideshow. Vistagen Therapeutics Vtgn Investor Presentation Slideshow

By Seekingalpha 2021-06-30

GuruFocus Screeners

My Screeners

Value Screens

Model Portfolios

Market Data

Economic Indicators

By Country

Articles

Submit Articles

VistaGen Therapeutics EBIT

VistaGen Therapeutics EBIT Historical Data

VistaGen Therapeutics EBIT Calculation

VistaGen Therapeutics EBIT Related Terms

VistaGen Therapeutics Business Description

VistaGen Therapeutics Headlines

VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors

VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder

VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B's Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain

Longwood Capital Partners LLC Buys VistaGen Therapeutics Inc, Seelos Therapeutics Inc, ESSA Pharma Inc, Sells Larimar Therapeutics Inc, Immunovant Inc, Sage Therapeutics Inc

VistaGen Therapeutics to Participate in Baird's 2021 Global Healthcare Conference

VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference

VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021

VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements

VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2

VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021

$VTGN - VistaGen Therapeutics (VTGN) Investor Presentation - Slideshow. Vistagen Therapeutics Vtgn Investor Presentation Slideshow

Sage Stock Declines on Late-Stage Depression Study Data

Will VistaGen Therapeutics, Inc. (VTGN) Report Negative Q2 Earnings? What You Should Know

Earnings Preview: VistaGen Therapeutics, Inc. (VTGN) Q3 Earnings Expected to Decline

Bristol Myers (BMY) Gets EC Nod for Opdivo's Label Expansion

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

New Strong Sell Stocks for March 11th

Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022

Robert W. Baird Thinks VistaGen Therapeutics� Stock is Going to Recover

$VTGN - VistaGen Therapeutics' (VTGN) CEO Shawn Singh on Q2 2022 Results - Earnings Call Transcript.…

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates

$VTGN - VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2021 Results - Earnings Call Transcript.…

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates

$VTGN - VistaGen: Patience Could Lead To Significant Upside. Vistagen Patience Lead To Significant Upside